Gefitinib, but not erlotinib, is a possible inducer of Fra-1-mediated interstitial lung disease

Yasunari Takada, Koichi Matsuo

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Gefitinib is an anticancer drug developed to inhibit the tyrosine kinase activity of the epidermal growth factor receptor (EGFR). Two structurally-related EGFR tyrosine kinase inhibitors, gefitinib (Iressa) and erlotinib (Tarceva), are used as oral chemotherapy by patients with non-small-cell lung cancer. Immediately after introduction of gefitinib to clinical practice, interstitial lung disease was identified as a life-threatening adverse effect, although this condition can be well managed. It is still unclear whether gefitinib and other EGFR inhibitors induce similar adverse effects in lung. We previously established mouse models of interstitial lung disease in which gefitinib induces expression of Fosl1 (which encodes the AP-1 transcription factor Fra-1) in the presence of exogenous or endogenous Toll-like receptor ligands, leading to abnormal cytokine and chemokine expression. Here, we compared and monitored the effects of EGFR inhibitors gefitinib, erlotinib and AG1517 (PD153035) on the mRNA expression levels of Fosl1, Tnf and Ccl2. Unexpectedly, gefitinib, but not the other tyrosine kinase inhibitors, elicited the Fosl1 expression profile proposed to be predictive of interstitial lung disease, suggesting that gefitinib-induced interstitial lung disease is an off-target effect not elicited by erlotinib.

Original languageEnglish
Pages (from-to)120-127
Number of pages8
JournalKeio Journal of Medicine
Volume61
Issue number4
DOIs
Publication statusPublished - 2012 Dec

Fingerprint

Interstitial Lung Diseases
Epidermal Growth Factor Receptor
Protein-Tyrosine Kinases
Erlotinib Hydrochloride
gefitinib
Toll-Like Receptors
Transcription Factor AP-1
Chemokines
Non-Small Cell Lung Carcinoma
Cytokines
Ligands
Drug Therapy
Lung
Messenger RNA

Keywords

  • EGFR inhibitor
  • Erlotinib
  • Gefitinib
  • Interstitial lung disease

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Gefitinib, but not erlotinib, is a possible inducer of Fra-1-mediated interstitial lung disease. / Takada, Yasunari; Matsuo, Koichi.

In: Keio Journal of Medicine, Vol. 61, No. 4, 12.2012, p. 120-127.

Research output: Contribution to journalArticle

@article{1855e68b09874ab9ab2b392431e99d24,
title = "Gefitinib, but not erlotinib, is a possible inducer of Fra-1-mediated interstitial lung disease",
abstract = "Gefitinib is an anticancer drug developed to inhibit the tyrosine kinase activity of the epidermal growth factor receptor (EGFR). Two structurally-related EGFR tyrosine kinase inhibitors, gefitinib (Iressa) and erlotinib (Tarceva), are used as oral chemotherapy by patients with non-small-cell lung cancer. Immediately after introduction of gefitinib to clinical practice, interstitial lung disease was identified as a life-threatening adverse effect, although this condition can be well managed. It is still unclear whether gefitinib and other EGFR inhibitors induce similar adverse effects in lung. We previously established mouse models of interstitial lung disease in which gefitinib induces expression of Fosl1 (which encodes the AP-1 transcription factor Fra-1) in the presence of exogenous or endogenous Toll-like receptor ligands, leading to abnormal cytokine and chemokine expression. Here, we compared and monitored the effects of EGFR inhibitors gefitinib, erlotinib and AG1517 (PD153035) on the mRNA expression levels of Fosl1, Tnf and Ccl2. Unexpectedly, gefitinib, but not the other tyrosine kinase inhibitors, elicited the Fosl1 expression profile proposed to be predictive of interstitial lung disease, suggesting that gefitinib-induced interstitial lung disease is an off-target effect not elicited by erlotinib.",
keywords = "EGFR inhibitor, Erlotinib, Gefitinib, Interstitial lung disease",
author = "Yasunari Takada and Koichi Matsuo",
year = "2012",
month = "12",
doi = "10.2302/kjm.2011-0009-OA",
language = "English",
volume = "61",
pages = "120--127",
journal = "Keio Journal of Medicine",
issn = "0022-9717",
publisher = "Keio University School of Medicine",
number = "4",

}

TY - JOUR

T1 - Gefitinib, but not erlotinib, is a possible inducer of Fra-1-mediated interstitial lung disease

AU - Takada, Yasunari

AU - Matsuo, Koichi

PY - 2012/12

Y1 - 2012/12

N2 - Gefitinib is an anticancer drug developed to inhibit the tyrosine kinase activity of the epidermal growth factor receptor (EGFR). Two structurally-related EGFR tyrosine kinase inhibitors, gefitinib (Iressa) and erlotinib (Tarceva), are used as oral chemotherapy by patients with non-small-cell lung cancer. Immediately after introduction of gefitinib to clinical practice, interstitial lung disease was identified as a life-threatening adverse effect, although this condition can be well managed. It is still unclear whether gefitinib and other EGFR inhibitors induce similar adverse effects in lung. We previously established mouse models of interstitial lung disease in which gefitinib induces expression of Fosl1 (which encodes the AP-1 transcription factor Fra-1) in the presence of exogenous or endogenous Toll-like receptor ligands, leading to abnormal cytokine and chemokine expression. Here, we compared and monitored the effects of EGFR inhibitors gefitinib, erlotinib and AG1517 (PD153035) on the mRNA expression levels of Fosl1, Tnf and Ccl2. Unexpectedly, gefitinib, but not the other tyrosine kinase inhibitors, elicited the Fosl1 expression profile proposed to be predictive of interstitial lung disease, suggesting that gefitinib-induced interstitial lung disease is an off-target effect not elicited by erlotinib.

AB - Gefitinib is an anticancer drug developed to inhibit the tyrosine kinase activity of the epidermal growth factor receptor (EGFR). Two structurally-related EGFR tyrosine kinase inhibitors, gefitinib (Iressa) and erlotinib (Tarceva), are used as oral chemotherapy by patients with non-small-cell lung cancer. Immediately after introduction of gefitinib to clinical practice, interstitial lung disease was identified as a life-threatening adverse effect, although this condition can be well managed. It is still unclear whether gefitinib and other EGFR inhibitors induce similar adverse effects in lung. We previously established mouse models of interstitial lung disease in which gefitinib induces expression of Fosl1 (which encodes the AP-1 transcription factor Fra-1) in the presence of exogenous or endogenous Toll-like receptor ligands, leading to abnormal cytokine and chemokine expression. Here, we compared and monitored the effects of EGFR inhibitors gefitinib, erlotinib and AG1517 (PD153035) on the mRNA expression levels of Fosl1, Tnf and Ccl2. Unexpectedly, gefitinib, but not the other tyrosine kinase inhibitors, elicited the Fosl1 expression profile proposed to be predictive of interstitial lung disease, suggesting that gefitinib-induced interstitial lung disease is an off-target effect not elicited by erlotinib.

KW - EGFR inhibitor

KW - Erlotinib

KW - Gefitinib

KW - Interstitial lung disease

UR - http://www.scopus.com/inward/record.url?scp=84874822529&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874822529&partnerID=8YFLogxK

U2 - 10.2302/kjm.2011-0009-OA

DO - 10.2302/kjm.2011-0009-OA

M3 - Article

VL - 61

SP - 120

EP - 127

JO - Keio Journal of Medicine

JF - Keio Journal of Medicine

SN - 0022-9717

IS - 4

ER -